Page last updated: 2024-12-06

quinalphos

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

quinalphos: RN given refers to cpd with locant for quinoxalinyl group in position 2; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26124
CHEMBL ID1893890
CHEBI ID8712
SCHEMBL ID18079
MeSH IDM0053600

Synonyms (94)

Synonym
AC-12671
BIDD:ER0041
o,o-diethyl-o-(2-quinoxalinyl) phosphorothioate
einecs 237-031-6
diethquinalphion
o,o-diethyl o-2-quinoxalinyl phosphorothioic acid ester
san 6626 i
diethquinalphione
wie oben
ekalux
chinalphos
spencer s-6538
ent 27394
o,o-diethyl-o-(2-quinoxalyl) phosphorothioate
sandoz 6538
bay 5821
s-6538 ,
san 6538 i
bay 77049
o,o-diethyl o-(2-chinoxalyl)-phosphorothioate
quinalphos [bsi:iso]
nsc 190986
quinalphos 25 ec
savall
o,o-diaethyl-o-(chinoxalyl-(2))-monothiophosphat [german]
ai3-27394
ekalux 25ec
brn 0754823
ccris 3398
quinaltaf
o,o-diethyl-o-2-quinoxalyl-thiophosphate
sra 7312
o,o-diethyl-o-(quinoxalinyl-(2))-thionophosphate
bayer 77049
phosphorothioic acid, o,o-diethyl o-2-quinoxalinyl ester
quinalphos
13593-03-8
bayrusil
diethyl o-(quinoxalin-2-yl) thiophosphate
o,o-diethyl o-quinoxalin-2-yl phosphorothioate
CHEBI:8712 ,
phosphorothioic acid, o,o-diethyl o-(2-quinoxalinyl) ester
o,o-diethyl o-quinoxalin-2-yl thiophosphate
diethyl o-(2-quinoxalyl) phosphorothioate
NCGC00164298-01
diethoxy-quinoxalin-2-yloxy-sulfanylidenephosphorane
inchi=1/c12h15n2o3ps/c1-3-15-18(19,16-4-2)17-12-9-13-10-7-5-6-8-11(10)14-12/h5-9h,3-4h2,1-2h3
jyquhifybatccy-uhfffaoysa-
NCGC00164298-02
guinalphos
unii-26s837727y
26s837727y ,
o,o-diaethyl-o-(chinoxalyl-(2))-monothiophosphat
5-23-11-00455 (beilstein handbook reference)
tox21_303270
dtxsid7024291 ,
dtxcid904291
cas-13593-03-8
NCGC00256999-01
NCGC00259577-01
tox21_202028
AKOS015960929
diethchinalphion
diethyl 2-quinoxalyl phosphorothionate
quinalphos [iso]
o,o-diethyl-o-quinoxal-2-yl thionophosphate
oleoekalux
o,o-diethyl o-2-quinoxalinyl phosphorothioate
kinalux
quinalfos
o,o-diethyl o-(2-quinoxalyl) phosphorothionate
bay-77049
san-6538
SCHEMBL18079
CHEMBL1893890
diethyl o-2-quinoxalinyl phosphorothioate
o,o-diethyl o-(quinoxalin-2-yl) thiophosphate
JYQUHIFYBATCCY-UHFFFAOYSA-N
diethyl o-quinoxalin-2-yl thionophosphate
quinolphos
o,o-diethyl o-(2-quinoxalinyl) thiophosphate #
san 6538
sandoz 6626
san 6626
quinalphos, pestanal(r), analytical standard
quinalphos 10 microg/ml in cyclohexane
J-006784
Q421631
o,o-diethyl o-(quinoxalin-2-yl) phosphorothioate
diethoxy-quinoxalin-2-yloxy-sulfanylidene-lambda5-phosphane
quinalphos 1000 microg/ml in acetone
FT-0742398
o,o-diethyl o-(2-quinoxalyl)phosphorothionate
diethoxy-quinoxalin-2-yloxy-sulfanylidene-$l^{5}-phosphane

Research Excerpts

Overview

Quinalphos is a long-term, wide-spectrum organophosphate insecticide with residual problems in the natural environment.

ExcerptReferenceRelevance
"Quinalphos is a long-term, wide-spectrum organophosphate insecticide with residual problems in the natural environment. "( Biodegradation and metabolic pathway of quinalphos by Cunninghamella elegans ATCC36112.
Kim, JH; Meng, M; Wu, Q; Zhang, Z; Zhu, Y, 2023
)
2.62
"Quinalphos is a synthetic organophosphate used as a broad spectrum insecticide and acaricide. "( Quinalphos induced oxidative stress and histoarcheitectural alterations in adult male albino rats.
Ahmed, RS; Arora, VK; Banerjee, BD; Jain, S; Subramaneyaan, M; Yadav, C, 2012
)
3.26

Treatment

Quinalphos treatment for 15 and 30 days resulted in a dose dependent significant increase in malondialdehyde (MDA) levels and glutathione-S-transferase (GST) activity. Treatment of quinalphas for 13 days failed to produce any effect on the relative weights of the testes and accessory sex glands.

ExcerptReferenceRelevance
"Quinalphos treatment for 15 and 30 days resulted in a dose dependent significant increase in malondialdehyde (MDA) levels and glutathione-S-transferase (GST) activity together with a concurrent decrease in ferric reducing ability of plasma (FRAP) and glutathione (GSH) content."( Quinalphos induced oxidative stress and histoarcheitectural alterations in adult male albino rats.
Ahmed, RS; Arora, VK; Banerjee, BD; Jain, S; Subramaneyaan, M; Yadav, C, 2012
)
2.54
"Treatment of quinalphos for 13 days failed to produce any effect on the relative weights of the testes and accessory sex glands."( Effect of quinalphos on testicular steroidogenesis in rats.
Bagchi, P; Chatterjee, S; Das, TK; Deb, C; Ray, A,
)
0.89

Toxicity

ExcerptReferenceRelevance
" The acute po LD50 of technical quinalphos was 19."( Acute and subchronic oral toxicity of technical quinalphos in rats.
Dikshith, TS; Gupta, KP; Kaushal, RA; Raizada, RB; Singh, RP; Srivastava, MK, 1993
)
0.83
" Pretreatment of rats with phenobarbitone (PB) or 3-methylcholanthrene (MC) (P450 inducers) prevented mortality caused by the LD50 dose of QP, whereas pretreatment with cobalt chloride (a P450 inhibitor) enhanced the mortality rate to 100% within 3 days."( Role of cytochrome P-450 in quinalphos toxicity: effect on hepatic and brain antioxidant enzymes in rats.
Das, M; Dwivedi, PD; Khanna, SK, 1998
)
0.59

Bioavailability

ExcerptReferenceRelevance
" A higher magnitude of inhibition of arginine deamination in the loamy sand than in the sandy loam soil could be due to greater bioavailability of the pesticides in the former, resulting from lesser sorption of the pesticides due to alkalinity of the soil and its low content of clay and organic carbon."( Influence of two insecticides, chlorpyrifos and quinalphos, on arginine ammonification and mineralizable nitrogen in two tropical soil types.
Gopal, M; Menon, P; Prasad, R, 2004
)
0.58

Dosage Studied

ExcerptRelevanceReference
" The metabolic intermediates of quinalphos in serum and urine of albino rats at different time intervals were identified after dosing the animals with 5 mg kg(-1) body weight."( In vitro and in vivo studies on degradation of quinalphos in rats.
Gupta, B; Kumar, R; Rani, M; Salunke, R, 2012
)
0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 3.1.1.7 (acetylcholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
acaricideA substance used to destroy pests of the subclass Acari (mites and ticks).
agrochemicalAn agrochemical is a substance that is used in agriculture or horticulture.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic thiophosphate
organothiophosphate insecticide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency63.26090.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency37.94790.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
RAR-related orphan receptor gammaMus musculus (house mouse)Potency32.21230.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency18.17660.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency36.69910.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency61.13060.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.27240.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency27.30600.000417.946075.1148AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.13560.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.78330.001530.607315,848.9004AID1224841; AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency50.71630.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency20.09060.000229.305416,493.5996AID743075; AID743077; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.89920.001024.504861.6448AID743215
aryl hydrocarbon receptorHomo sapiens (human)Potency16.29360.000723.06741,258.9301AID651777; AID743085; AID743122
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency54.94100.057821.109761.2679AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency58.93530.000323.4451159.6830AID743065; AID743066; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency57.71100.037617.082361.1927AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency67.45340.000627.21521,122.0200AID720636; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (96)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (13.54)18.7374
1990's22 (22.92)18.2507
2000's28 (29.17)29.6817
2010's23 (23.96)24.3611
2020's10 (10.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.94 (24.57)
Research Supply Index4.66 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index102.44 (26.88)
Search Engine Supply Index3.30 (0.95)

This Compound (41.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies5 (4.76%)4.05%
Observational0 (0.00%)0.25%
Other100 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]